The study focuses on adults who have Irritable Bowel Syndrome-Diarrhea, a condition that causes frequent loose stools, abdominal pain, and urgency. The treatment being tested is an injectable medication called Brenipatide, which contains the experimental substance LY3537031. A matching placebo is used for comparison.
The purpose of the study is to determine whether the investigational drug improves symptoms compared with the control. Participants are randomly assigned to receive either the medication or the placebo, and neither the participants nor the study staff know which is given (double‑blind). The drug is administered by a small injection under the skin (subcutaneous) on a regular schedule over several weeks, with follow‑up visits to check health and record daily bowel habits.
During the study, participants keep a simple diary of stool frequency, consistency, and pain, and they attend periodic clinic visits for safety checks, such as brief physical examinations and basic laboratory tests. The overall study period lasts about four months, after which the collected information is used to assess the medication’s effect on the condition.
Belgium 
Germany 
Spain 
